Epilepsy: Epidemiology Report and Forecast to 2035

Analyze epilepsy epidemiology across seven major markets with active diagnosed prevalent cases segmented by age, sex, seizure type, and key epilepsy syndromes through 2035.

Why Does Epilepsy Epidemiology Matter?

Epilepsy is one of the most widespread neurological disorders globally, characterized by recurrent, unpredictable seizures caused by abnormal electrical activity in the brain. Understanding the size and composition of the diagnosed patient population is critical for assessing future healthcare and treatment needs.

In the seven major markets (7MM), active diagnosed prevalent cases of epilepsy are forecast to increase from 6.2 million in 2025 to 6.5 million in 2035, representing an annual growth rate (AGR) of 0.49%.

This report provides a detailed 10-year epidemiology forecast across the US, France, Germany, Italy, Spain, the UK, and Japan, with patient populations segmented by age, sex, seizure type, and selected epilepsy syndromes.

Key Insights in the Epilepsy Epidemiology Landscape

The report provides insight into:

• Active diagnosed prevalent cases of epilepsy from 2025–2035
• Epidemiology trends across the 7MM
• Patient population trends across the five major European markets
• Age and sex distribution of diagnosed patients
• Epilepsy cases by seizure type
• Generalized, focal, and unclassified/unknown seizures
• Diagnosed prevalent cases of Dravet syndrome (DS)
• Diagnosed prevalent cases of Lennox-Gastaut syndrome (LGS)
• Key epilepsy risk factors and historical trends
• Country-level epidemiology differences
• Forecast changes in patient populations through 2035

Scope

What Will You Learn from This Epilepsy Epidemiology Report?

This report provides insight into:

• The current diagnosed epilepsy population across the 7MM
• How active diagnosed prevalent cases are expected to change through 2035
• Patient population trends across the US, 5EU, and Japan
• Age-specific and sex-specific patient populations
• The distribution of epilepsy by seizure type
• Population trends for generalized, focal, and unclassified seizures
• Epidemiology of Dravet syndrome and Lennox-Gastaut syndrome
• Markets with the largest diagnosed patient populations
• Markets showing the fastest population growth
• Risk factors and historical epidemiological trends
• Patient population opportunities relevant to epilepsy therapeutics

Who Should Buy This Epilepsy Epidemiology Report?

This report may be valuable for:

• Pharmaceutical and biopharmaceutical companies
• Neurology and epilepsy therapeutics developers
• Clinical development teams
• Commercial strategy teams
• Market intelligence teams
• Business development teams
• Sales and marketing teams
• Healthcare investors
• Epidemiology and forecasting teams
• Consultants and industry advisors
  

  

How Companies Use This Epilepsy Epidemiology Analysis

Companies can use the report to quantify patient populations, understand demographic trends, and support strategic planning for epilepsy-related products and therapies.

For example:

• Pharmaceutical companies can assess patient population trends to support product and portfolio planning.
• Epilepsy therapeutics developers can evaluate population size and demographic characteristics across key markets.
• Clinical development teams can use epidemiological segmentation to inform development strategies.
• Commercial strategy teams can assess market-level patient populations and future growth.
• Sales and marketing teams can identify age groups and markets offering stronger opportunities.
• Business development teams can use patient population forecasts to evaluate potential opportunities.
• Investors can assess the scale and evolution of the epilepsy patient population across major markets.
• Market intelligence teams can track changes in diagnosed prevalence and demographic composition through 2035.
• Consultants can use epidemiological insights to support healthcare strategy and market assessments.

Reasons to Buy

Benchmark Epilepsy Epidemiology Across Seven Major Markets

The report enables users to benchmark epilepsy epidemiology across the US, France, Germany, Italy, Spain, the UK, and Japan.

Benchmarking includes:

• Active diagnosed prevalent cases
• Annual growth rates
• Age distribution
• Sex distribution
• Seizure type
• Generalized seizures
• Focal seizures
• Unclassified/unknown seizures
• Dravet syndrome cases
• Lennox-Gastaut syndrome cases
• Historical and forecast trends

The analysis helps identify markets with the largest patient populations and compare how epilepsy prevalence is expected to evolve across the 7MM.

Built on GlobalData Epidemiology Intelligence

GlobalData’s Epilepsy Epidemiology Analysis provides a 10-year forecast of active diagnosed prevalent cases across the seven major markets from 2025–2035.

The model segments the patient population by sex and age, covering adults from age 18 through 85 years and older, as well as by seizure type. It also provides diagnosed prevalent cases for Dravet syndrome and Lennox-Gastaut syndrome across the adult population.

Act Now to Identify Opportunities in the Epilepsy Market

The epilepsy patient population is expected to continue growing across most of the 7MM through 2035, creating an evolving landscape for healthcare and therapeutic planning.

Use GlobalData’s Epilepsy Epidemiology Analysis to quantify patient populations, identify high-opportunity age groups and markets, understand seizure-type distributions, and support product design, pricing, launch, sales, and marketing strategies.